Based on results from clinical trials including 1725 patients approximately 8% of patients treated with NeoRecormon are expected to experience adverse reactions.
Tuginedes 1725 osalejaga kliinilise uuringu andmetele võivad kõrvaltoimed tekkida ligikaudu 8% - l NeoRecormon- ravi saavatest patsientidest.